Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Inyta

Photo of Tim Wright plus title of talk

MFN Pricing Is Moving Fast – Here’s What Matters

With GENEROUS, GUARD, and GLOBE all released since December, 185 pages of policy will materially impact U.S. drug pricing — and yes, it's a lot to digest. In a new...

Genesis Research Group

- PMLiVE

Sanofi and Regeneron’s Dupixent receives positive NICE final draft guidance for COPD

Around 1.4 million people in the UK are diagnosed with COPD, with two million thought to be undiagnosed

- PMLiVE

ISPOR’s 2026–2027 HEOR Trends report: The Era of Evidence Judgment

In response to ISPOR’s recently published 2026-2027 HEOR Trends, David Miller, CEO, Genesis Research Group, suggests that we’re no longer being evaluated on our ability to produce data, but on...

Genesis Research Group

- PMLiVE

Pfizer’s Braftovi combination therapy shows positive results for colorectal cancer

Colorectal cancer is the third most common cancer globally, with approximately 1.8 million people diagnosed in 2022

Headshot of Sarah Theobald with text reading 'Healthcare communications trends in 2026'

What will healthcare communications look like in 2026? Amiculum’s prediction of upcoming trends

By Sarah Theobald

Amiculum

- PMLiVE

Pfizer’s Hympavzi significantly reduces bleeds in haemophilia patients

Over 800,000 people worldwide live with haemophilia

- PMLiVE

Does real-world use of AI in systematic literature reviews result in time and cost savings?

By Manca Povsic and Emma Griffiths

Amiculum

- PMLiVE

Pfizer’s PADCEV gets FDA approval for bladder cancer

Bladder cancer affects more than 614,000 people globally each year

Quote from the article: Without adapting JCA to include assessment of real-world data and broader benefits, vaccines may be undervalued

Is Joint Clinical Assessment (JCA) appropriate for assessing the broader value of vaccines?

By Emily Morton-West

Amiculum

- PMLiVE

Pfizer and Metsera agree on merger after bidding war between Pfizer and Novo Nordisk

The Pfizer bid was chosen by Metsera after a concern was raised about US antitrust laws regarding the Novo Nordisk offer

Genesis giveaway of a minifigure

Genesis Research Group contributes strong scientific program to ISPOR Europe and warmly invites visitors to booth 212

Genesis Research Group is proud to be attending ISPOR Europe 2025 in Glasgow from 10-12th November with a strong scientific program that includes an HEOR Theater session, contributions to 10...

Genesis Research Group

- PMLiVE

Minds + Assembly Launches Assembled Intelligence and Adds Stratevi to Expand Market Access and HEOR Solutions

New York, NY — 10.23.2025 — Minds + Assembly, a leading healthcare marketing firm, today announced the launch of Assembled Intelligence, an integrated communications and commercialization platform designed to unite...

BOLDSCIENCE

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links